Evaluation of medical countermeasures against ebolaviruses in nonhuman primate models

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Several ebolavirus species, with varying lethality rates, have caused sporadic outbreaks in Africa resulting in human disease. Ebolaviruses also have the potential for use as biological weapons. Currently, there are no licensed vaccines or therapeutics to respond to outbreaks or deliberate misuse of ebolaviruses. Vaccine or therapeutic efficacy testing of medical countermeasures against ebolaviruses requires an animal model of disease; in vitro testing in cell culture cannot reproduce the complicated balance between host-pathogen interactions required for the ultimate licensure of a countermeasure. Depending on the target of the countermeasure, demonstration of efficacy in the nonhuman primate ebolavirus disease models will most likely be required before licensure. Here, we describe the selection and use of nonhuman primates for vaccine and therapeutic studies against ebolaviruses.

Original languageEnglish (US)
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages293-307
Number of pages15
Volume1628
DOIs
StatePublished - 2017

Publication series

NameMethods in Molecular Biology
Volume1628
ISSN (Print)1064-3745

Fingerprint

Ebolavirus
Primates
Vaccines
Licensure
Primate Diseases
Disease Outbreaks
Biological Warfare Agents
Host-Pathogen Interactions
Animal Disease Models
Therapeutics
Cell Culture Techniques

Keywords

  • Bundibugyo
  • Ebola
  • Ebolavirus
  • Nonhuman primate model
  • Sudan
  • Therapeutic
  • Vaccine
  • Zaire

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Mire, C., & Geisbert, T. (2017). Evaluation of medical countermeasures against ebolaviruses in nonhuman primate models. In Methods in Molecular Biology (Vol. 1628, pp. 293-307). (Methods in Molecular Biology; Vol. 1628). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-7116-9_24

Evaluation of medical countermeasures against ebolaviruses in nonhuman primate models. / Mire, Chad; Geisbert, Thomas.

Methods in Molecular Biology. Vol. 1628 Humana Press Inc., 2017. p. 293-307 (Methods in Molecular Biology; Vol. 1628).

Research output: Chapter in Book/Report/Conference proceedingChapter

Mire, C & Geisbert, T 2017, Evaluation of medical countermeasures against ebolaviruses in nonhuman primate models. in Methods in Molecular Biology. vol. 1628, Methods in Molecular Biology, vol. 1628, Humana Press Inc., pp. 293-307. https://doi.org/10.1007/978-1-4939-7116-9_24
Mire C, Geisbert T. Evaluation of medical countermeasures against ebolaviruses in nonhuman primate models. In Methods in Molecular Biology. Vol. 1628. Humana Press Inc. 2017. p. 293-307. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-4939-7116-9_24
Mire, Chad ; Geisbert, Thomas. / Evaluation of medical countermeasures against ebolaviruses in nonhuman primate models. Methods in Molecular Biology. Vol. 1628 Humana Press Inc., 2017. pp. 293-307 (Methods in Molecular Biology).
@inbook{6f37515451524d82a4fde867b89fe69a,
title = "Evaluation of medical countermeasures against ebolaviruses in nonhuman primate models",
abstract = "Several ebolavirus species, with varying lethality rates, have caused sporadic outbreaks in Africa resulting in human disease. Ebolaviruses also have the potential for use as biological weapons. Currently, there are no licensed vaccines or therapeutics to respond to outbreaks or deliberate misuse of ebolaviruses. Vaccine or therapeutic efficacy testing of medical countermeasures against ebolaviruses requires an animal model of disease; in vitro testing in cell culture cannot reproduce the complicated balance between host-pathogen interactions required for the ultimate licensure of a countermeasure. Depending on the target of the countermeasure, demonstration of efficacy in the nonhuman primate ebolavirus disease models will most likely be required before licensure. Here, we describe the selection and use of nonhuman primates for vaccine and therapeutic studies against ebolaviruses.",
keywords = "Bundibugyo, Ebola, Ebolavirus, Nonhuman primate model, Sudan, Therapeutic, Vaccine, Zaire",
author = "Chad Mire and Thomas Geisbert",
year = "2017",
doi = "10.1007/978-1-4939-7116-9_24",
language = "English (US)",
volume = "1628",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "293--307",
booktitle = "Methods in Molecular Biology",

}

TY - CHAP

T1 - Evaluation of medical countermeasures against ebolaviruses in nonhuman primate models

AU - Mire, Chad

AU - Geisbert, Thomas

PY - 2017

Y1 - 2017

N2 - Several ebolavirus species, with varying lethality rates, have caused sporadic outbreaks in Africa resulting in human disease. Ebolaviruses also have the potential for use as biological weapons. Currently, there are no licensed vaccines or therapeutics to respond to outbreaks or deliberate misuse of ebolaviruses. Vaccine or therapeutic efficacy testing of medical countermeasures against ebolaviruses requires an animal model of disease; in vitro testing in cell culture cannot reproduce the complicated balance between host-pathogen interactions required for the ultimate licensure of a countermeasure. Depending on the target of the countermeasure, demonstration of efficacy in the nonhuman primate ebolavirus disease models will most likely be required before licensure. Here, we describe the selection and use of nonhuman primates for vaccine and therapeutic studies against ebolaviruses.

AB - Several ebolavirus species, with varying lethality rates, have caused sporadic outbreaks in Africa resulting in human disease. Ebolaviruses also have the potential for use as biological weapons. Currently, there are no licensed vaccines or therapeutics to respond to outbreaks or deliberate misuse of ebolaviruses. Vaccine or therapeutic efficacy testing of medical countermeasures against ebolaviruses requires an animal model of disease; in vitro testing in cell culture cannot reproduce the complicated balance between host-pathogen interactions required for the ultimate licensure of a countermeasure. Depending on the target of the countermeasure, demonstration of efficacy in the nonhuman primate ebolavirus disease models will most likely be required before licensure. Here, we describe the selection and use of nonhuman primates for vaccine and therapeutic studies against ebolaviruses.

KW - Bundibugyo

KW - Ebola

KW - Ebolavirus

KW - Nonhuman primate model

KW - Sudan

KW - Therapeutic

KW - Vaccine

KW - Zaire

UR - http://www.scopus.com/inward/record.url?scp=85020193274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020193274&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-7116-9_24

DO - 10.1007/978-1-4939-7116-9_24

M3 - Chapter

VL - 1628

T3 - Methods in Molecular Biology

SP - 293

EP - 307

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -